C. LAURENT No1affiliation
S. LE1GOUILL Janssen1A1Cilag Consultant
Roche Consultant
Servier Consultant
Kite1Gilead Consultant
Novartis1 Consultant
I.1S. LOSSOS Janssen1Scientific Scientific1Advisory1Bd.
Karyopharm Scientific1Advisory1Bd.
Seattle1Genetics Scientific1Advisory1Bd.
Verastem Scientific1Advisory1Bd.
S. LUMINARI Roche1 Consultant,Scientific1Advisory1Bd.
Celgene1A1BMS Consultant,Scientific1Advisory1Bd.
Gilead Scientific1Advisory1Bd.
Janssen Scientific1Advisory1Bd.
M. MEIGNAN Roche Research1Support,1Consultant
Keosys Research1Support
T. MOLINA Merck Scientific1Advisory1Bd.
Sanofi Consultant
F. MORSCHHAUSER Celgene Scientific1Advisory1Bd.
Roche1/1Genentech Scientific1Advisory1Bd.
BMS Scientific1Advisory1Bd.
Janssen Other
Gilead Consultant
Epizyme Scientific1Advisory1Bd.
Novartis1 Other
O. O'CONNOR TG1Therapeutics Employee,1other
Kymera Advisory1Bd.,1Other
Nomocan Other
Myeloid1Therapeutics Advisory1Bd.,1Other
Mundipharma Consultant
Celgene1A1BMS Research1Support
Merck Research1Support
Astex Research1Support
Servier Consultant
L. PASQUALUCCI Astra1Zeneca Research1Support
Sanofi Research1Support
S. PILERI Roche1 Speakers'1Bureau
Nanostring Scientific1Advisory1Bd.
Celgene Scientific1Advisory1Bd.
M. PONZONI No1affiliation
M. RADERER Eli1Lilly Scientific1Advisory1Bd.
D. ROSSI Abbvie Research1Support,1Scientific1Advisory1Bd.
Astra1Zeneca Research1Support,1Scientific1Advisory1Bd.
Janssen Research1Support,1Scientific1Advisory1Bd.
Gilead Research1Support,1Scientific1Advisory1Bd.
Verastem Scientific1Advisory1Bd.
Loxo Scientific1Advisory1Bd.
Roche Scientific1Advisory1Bd.
Celestia Research1Support,1Scientific1Advisory1Bd.
G. SALLES Abbvie1 Scientific1Advisory1Bd.
Autolus1 Scientific1Advisory1Bd.
BMS/Celgene1 Scientific1Advisory1Bd.,1Other
Debiopharm1 Scientific1Advisory1Bd.
Genmab1 Scientific1Advisory1Bd.
Gilead/Kite1 Scientific1Advisory1Bd.,1Other
Epizyme1 Scientific1Advisory1Bd.
Janssen1 Scientific1Advisory1Bd.,1Other
Morphosys1 Scientific1Advisory1Bd.,1Other
Novartis1 Scientific1Advisory1Bd.,1Other
Roche1 Scientific1Advisory1Bd.,1Other
Takeda1 Scientific1Advisory1Bd.
S. SCHUSTER AlloGene Consultant
AstraZeneca Consultant
Beigene Consultant
Celgene Research1Support,1Consultant
Genentech/Roche Research1Support,1Consultant,1Scientific1Advisory1Bd.
Juno1Therapeutics1 Research1Support,1Consultant,1Scientific1Advisory1Bd.
Loxo1Oncology Consultant,Scientific1Advisory1Bd.
Nordic1Nanovector Scientific1Advisory1Bd.
Novartis Research1Support,1Consultant,1Scientific1Advisory1Bd.
Regeneron Consultant
Tessa1Therapeutics Consultant
C. THIEBLEMONT Cellectis Speakers'1Bureau
Gilead Scientific1Advisory1Bd.,1Other
Novartis Scientific1Advisory1Bd.,1Other
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES